Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer

被引：0
|
作者：
Mohammed A Aleskandarany
Andrew R Green
Ahmed A Benhasouna
Fabricio F Barros
Keith Neal
Jorge S Reis-Filho
Ian O Ellis
Emad A Rakha
机构：
[1] University of Nottingham and Nottingham University Hospitals NHS Trust,Department of Histopathology, School of Molecular Medical Sciences, Queens Medical Centre
[2] Menoufia University,Pathology Department, Faculty of Medicine
[3] Shebin El-Kom,Occupational Health, School of Molecular Medical Sciences, Queens Medical Centre
[4] University of Nottingham and Nottingham University Hospitals NHS Trust,Breakthrough Breast Cancer Research Centre
[5] Institute of Cancer Research,undefined
来源：
Breast Cancer Research | / 14卷
关键词：
Breast Cancer; Mitotic Count; Breast Cancer Specific Survival; Luminal Tumor; Invasive Breast Cancer Case;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients
    Anna Machleidt
    Stefan Buchholz
    Simone Diermeier-Daucher
    Florian Zeman
    Olaf Ortmann
    Gero Brockhoff
    BMC Cancer, 13
  • [22] Sequence of therapy impact on older women with comorbidities and triple-negative or HER2-positive breast cancer
    Tamirisa, Nina
    Dong, Wenli
    Shen, Yu
    Lin, Heather
    Shaitelman, Simona F.
    Babiera, Gildy
    Bedrosian, Isabelle
    NPJ BREAST CANCER, 2025, 11 (01)
  • [23] Clinical outcomes in HER2-positive and triple-negative breast cancer: Assessing racial disparities.
    Sarma, Maithreyi
    Ronghe, Ashwini
    Nasir, Samar
    Kapoor, Ankita
    Attwood, Kristopher
    Gandhi, Shipra
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Targeting triple-negative breast cancer by conversion into HER2-positive cancer: A novel therapeutic approach.
    Bernemann, Christof
    Huelsewig, Carolin
    Kiesel, Ludwig
    Liedtke, Cornelia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer
    Miglietta, Federica
    Dieci, Maria Vittoria
    Griguolo, Gaia
    Guarneri, Valentina
    CANCER TREATMENT REVIEWS, 2021, 98
  • [26] Neoadjuvant therapy for triple negative and HER2-positive early breast cancer
    Harbeck, Nadia
    Gluz, Oleg
    BREAST, 2017, 34 : S99 - S103
  • [27] Prognostic significance of basal and luminal markers in triple-negative breast cancer
    Kang, S. H.
    Lee, S. J.
    Bae, Y. K.
    EJC SUPPLEMENTS, 2008, 6 (07): : 187 - 188
  • [28] Prognostic significance of basal and luminal markers in triple-negative breast cancer
    Bae, Y. K.
    Kim, J. M.
    Kang, S. H.
    Lee, S. J.
    Gabrielson, E.
    MODERN PATHOLOGY, 2008, 21 : 20A - 20A
  • [29] Prognostic significance of basal and luminal markers in triple-negative breast cancer
    Bae, Y. K.
    Kim, J. M.
    Kang, S.
    Lee, S. J.
    Gabrielson, E.
    LABORATORY INVESTIGATION, 2008, 88 : 20A - 20A
  • [30] Establishment and characterization of novel highly aggressive HER2-positive and triple-negative breast cancer cell lines
    Thongchot, Suyanee
    Jamjuntra, Pranisa
    Prasopsiri, Jaturawitt
    Thuwajit, Peti
    Sawasdee, Nunghathai
    Poungvarin, Naravat
    Warnnissorn, Malee
    Sa-Nguanraksa, Doonyapat
    O-Charoenrat, Pornchai
    Yenchitsomanus, Pa-Thai
    Thuwajit, Chanitra
    ONCOLOGY REPORTS, 2021, 46 (06)
12345